Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1/2 6Phase NA 4Phase 3 3Phase 1 3Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Dexamethasone 8daratumumab 5Lenalidomide 5Bortezomib 5Thalidomide 4Cyclophosphamide 4carfilzomib 2Melphalan 2Calcium Dobesilate 2trametinib 1tanespimycin 1pomalidomide 1fludarabine 1dabrafenib 1cobimetinib 1Whole-Body Irradiation 1Vemurafenib 1Stem Cell Transplantation 1Rivaroxaban 1Mesna 1MAGEA3 protein, human 1Lenograstim 1Human Growth Hormone 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Busulfan 1Bone Marrow Transplantation 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Multiple Myeloma × Stem Cell Transplantation × Clear all
NCT00177047 2021-11-09

Autologous Transplant for Multiple Myeloma

Masonic Cancer Center, University of Minnesota

Phase 2/3 Completed
363 enrolled 25 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡